This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignees: Teijin Pharma Limited, Institute of Science Tokyo. Active years: 2017-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2026
Title: Yuki Miyazawa: Innovator in Pharmaceutical Crystallization
Introduction
Yuki Miyazawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical crystallization, holding a total of 3 patents. His work focuses on developing novel compounds with therapeutic applications.
Latest Patents
Miyazawa's latest patents include a crystal of a pyrido[3,4-d]pyrimidine derivative, which exhibits excellent CDK 4/6 inhibitory activity. This innovative compound is represented by a specific formula where R can be a hydrogen atom or a Calkyl group, and L can represent a single bond or a Calkylene group. Another notable patent is for a crystal of an azole benzene derivative, which is useful as a therapeutic agent for conditions such as gout and hyperuricemia.
Career Highlights
Yuki Miyazawa is currently employed at Teijin Pharma Limited, where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on drug development and therapeutic applications.
Collaborations
Miyazawa collaborates with talented individuals in his field, including Naoki Yajima and Asahi Kawana, who contribute to his research endeavors.
Conclusion
Yuki Miyazawa's contributions to pharmaceutical crystallization and his innovative patents highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile